Filtered By:
Drug: Bupropion

This page shows you your search results in order of date.

Order by Relevance | Date

Total 21 results found since Jan 2013.

Use of antidepressants in unipolar depression in the elderly
CONCLUSIONS: Unipolar major depressive episodes in the elderly are frequent and their medicinal treatment has specific features. Knowing the specificities of antidepressant use in the elderly allows to optimize its efficiency and to limit the risk of inappropriate prescription leading to harmful adverse effects.PMID:35153054 | DOI:10.1016/j.encep.2021.11.006
Source: L Encephale - February 14, 2022 Category: Psychiatry Authors: A Pericaud C Straczek F Montastruc M Leboyer A Yrondi C Arbus Source Type: research

Is bupropion useful in the treatment of post-stroke thalamic apathy? A case report and considerations.
Authors: Aragona B, De Luca R, Piccolo A, Le Cause M, Destro M, Casella C, Filoni S, Calabrò RS Abstract Post-stroke apathy is considered to be one of the clinical consequences of lesions affecting the structures of the prefrontal cortex, basal ganglia, thalamus and limbic system. However, there is no current consensus on the treatment of post-stroke apathy, which mainly depends on the underlying etiology and comorbidities. A 62-year-old man, affected by hemorrhagic stroke in the left thalamus, presented with mood depression, anhedonia, hyporexia and marked apathy. The patient underwent clinical evaluation before ...
Source: Functional Neurology - January 23, 2019 Category: Neurology Tags: Funct Neurol Source Type: research

Clinical Management of Bleeding Risk With Antidepressants.
CONCLUSIONS: Clinicians must be aware of the risk of bleeding with SRI use, especially for patients taking NSAIDs. Patient education is prudent for those prescribed NSAIDs and SRIs concurrently. PMID: 30081645 [PubMed - as supplied by publisher]
Source: The Annals of Pharmacotherapy - August 6, 2018 Category: Drugs & Pharmacology Authors: Bixby AL, VandenBerg A, Bostwick JR Tags: Ann Pharmacother Source Type: research

Modafinil for the Improvement of Patient Outcomes Following Traumatic Brain Injury
Conclusion. Modafinil is a central nervous system stimulant with well-established effectiveness in the treatment of narcolepsy and shift-work sleep disorder. There is conflicting evidence about the benefits of modafinil in the treatment of fatigue and EDS secondary to TBI. One randomized, controlled study states that modafinil does not significantly improve patient wakefulness, while another concludes that modafinil corrects EDS but not fatigue. An observational study provides evidence that modafinil increases alertness in fatigued patients with past medical history of brainstem diencephalic stroke or multiple sclerosis. ...
Source: Innovations in Clinical Neuroscience - April 1, 2018 Category: Neuroscience Authors: ICNS Online Editor Tags: Current Issue Review excessive daytime sleep fatigue head injury modafinil stroke TBI traumatic brain injury Source Type: research

Cost ‐effectiveness of alternative smoking cessation scenarios in Spain: results from the EQUIPTMOD
ConclusionsAccording to the EQUIPTMOD modelling tool it would be cost‐effective for the Spanish authorities to expand the reach of existing GP brief interventions for smoking cessation, provide pro‐active telephone support, and reimburse smoking cessation medication to smokers trying to stop. Such policies would more than pay for themselves in the long run.
Source: Addiction - March 13, 2018 Category: Addiction Authors: Marta Trapero ‐Bertran, Celia Muñoz, Kathryn Coyle, Doug Coyle, Adam Lester‐George, Reiner Leidl, Bertalan Németh, Kei‐Long Cheung, Subhash Pokhrel, Ángel Lopez‐Nicolás Tags: Research Report Source Type: research

Estimates of costs for modelling return on investment from smoking cessation interventions
ConclusionsCosts of treating smoking‐attributable diseases as well as the costs of implementing smoking cessation interventions vary substantially across Hungary, Netherlands, Germany, Spain and England. Estimates for the costs of these diseases and interventions can contribute to return on investment estimates in support of national or regional policy decisions.
Source: Addiction - March 13, 2018 Category: Addiction Authors: Marta Trapero ‐Bertran, Reiner Leidl, Celia Muñoz, Puttarin Kulchaitanaroaj, Kathryn Coyle, Maximilian Präger, Judit Józwiak‐Hagymásy, Kei Long Cheung, Mickael Hiligsmann, Subhash Pokhrel, Tags: Research Report Source Type: research

Wants Talk Psychotherapy but Cannot Talk: EMDR for Post-stroke Depression with Expressive Aphasia
CONCLUSION This is the first reported case demonstrating that EMDR can be effective for depression, even in those with severe expressive aphasia. In our case, there was no reluctance to disclose information, simply a neurological inability to do so. Through preparation, patience, perseverance, and plasticity (clinician flexibility, though perhaps also neuroplasticity), the patient’s PSD gradually improved, and she was able to reinvent her life within her limitations. ACKNOWLEDGMENTS The authors gratefully acknowledge Eugene Schwartz, E.C. Hurley, and Mark Hubner for providing consultation during patient care. REFERENCES ...
Source: Innovations in Clinical Neuroscience - February 1, 2018 Category: Neuroscience Authors: ICN Online Editor Tags: Case Report Current Issue Neurologic Systems and Symptoms Neurology Psychotherapy Stroke aphasia depression EMDR Source Type: research

CNS Summit 2017 Abstracts of Poster Presentations
Conclusion: This novel technology discriminates and quantifies subtle differences in behavior and neurological impairments in subjects afflicted with neurological injury/disease. KINARM assessments can be incorporated into multi-center trials (e.g., monitoring stroke motor recovery: NCT02928393). Further studies will determine if KINARM Labs can demonstrate a clinical effect with fewer subjects over a shorter trial period. Disclosures/funding: Dr. Stephen Scott is the inventor of KINARM and CSO of BKIN Technologies.   Multiplexed mass spectrometry assay identifies neurodegeneration biomarkers in CSF Presenter: Chelsky...
Source: Innovations in Clinical Neuroscience - November 1, 2017 Category: Neuroscience Authors: ICNS Online Editor Tags: Assessment Tools biomarkers Cognition Current Issue Drug Development General Genetics Medical Issues Neurology Patient Assessment Psychopharmacology Scales Special Issues Supplements Trial Methodology clinical trials CNS Su Source Type: research

Cardiovascular adverse events in the drug ‐development program of bupropion for smoking cessation: A systematic retrospective adjudication effort
Conclusions CV events in bupropion clinical trials for smoking cessation were uncommon, with no observed increase among subjects assigned to bupropion vs placebo. However, this effort was limited by a paucity of quality data.
Source: Clinical Cardiology - June 12, 2017 Category: Cardiology Authors: Jessie Kittle, Renato D. Lopes, Mingyan Huang, Marsha L. Marquess, Matthew D. Wilson, John Ascher, Alok Krishen, Vic Hasselblad, Brad J. Kolls, Matthew T. Roe, Darren K. McGuire, Stuart D. Russell, Kenneth W. Mahaffey Tags: CLINICAL INVESTIGATIONS Source Type: research

How to Quit Smoking
By Stacy Simon Tobacco use remains the single largest preventable cause of disease and premature death in the United States. Since the release of the Surgeon General’s Report on Smoking and Health 50 years ago, there have been 20 million deaths due to tobacco. Almost half the deaths from 12 different types of cancer combined – including lung, voice box, throat, esophagus, and bladder cancers – are attributable to cigarette smoking alone. In addition to cancer, smoking greatly increases the risk of debilitating long-term lung diseases like emphysema and chronic bronchitis. It also raises the risk for heart...
Source: American Cancer Society :: News and Features - November 16, 2016 Category: Cancer & Oncology Tags: Smoking/Tobacco Source Type: news

Pharmacologic Approaches to Weight Management: Recent Gains and Shortfalls in Combating Obesity
This article reviews recent literature in the field of Obesity Medicine and highlights important findings from clinical trials. Future directions in the pharmacologic management of obesity are presented along with new diabetes medications that promote weight loss and reduce cardiovascular mortality.
Source: Current Atherosclerosis Reports - May 14, 2016 Category: Cardiology Source Type: research

Evolution of Pharmacological Obesity Treatments: Focus on Adverse Side‐Effect Profiles
ABSTRACT Pharmacotherapy directed toward reducing body weight may provide benefits for both curbing obesity and lowering the risk of obesity‐associated co‐morbidities. However, many weight loss medications have been withdrawn from the market due to serious adverse effects. Examples include pulmonary hypertension (aminorex), cardiovascular toxicity, e.g. flenfluramine‐induced valvopathy, stroke (phenylpropanolamine), excess non‐fatal cardiovascular events (sibutramine), and neuro‐psychiatric issues (rimonabant ‐ approved in Europe, but not in the US). This negative experience has helped mold the current drug dev...
Source: Diabetes, Obesity and Metabolism - March 1, 2016 Category: Endocrinology Authors: Andrew J. Krentz, Ken Fujioka, Marcus Hompesch Tags: REVIEW ARTICLE Source Type: research

Study: Nicotine Patch Works as Well as Chantix to Help Quit Smoking
This study confirms that FDA-approved medications are effective in helping smokers quit,” said Lee Westmaas, PhD, American Cancer Society director of tobacco control research. “Smokers should seriously consider using medications if they are finding it difficult to quit without any help. The most effective approach to quitting is using medications in combination with counseling such as from a quit-line.”RESOURCES: How to Quit Smoking Quit-smoking medicationsResearch shows that using a medication to help you quit smoking can double your chances of being successful.The US Food and Drug Administration (...
Source: American Cancer Society :: News and Features - February 2, 2016 Category: Cancer & Oncology Tags: Smoking/Tobacco Source Type: news

Antidepressant Medication Use and Its Association With Cardiovascular Disease and All-Cause Mortality in the Reasons for Geographic and Racial Differences in Stroke (REGARDS) Study.
CONCLUSIONS: In fully adjusted models, antidepressant use was associated with a small increase in all-cause mortality. PMID: 26783360 [PubMed - as supplied by publisher]
Source: The Annals of Pharmacotherapy - January 18, 2016 Category: Drugs & Pharmacology Authors: Hansen RA, Khodneva Y, Glasser SP, Qian J, Redmond N, Safford MM Tags: Ann Pharmacother Source Type: research